Alzheimer Disease
📧 Sign up to get email alerts when something new happens for Alzheimer Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2016-05-03Clinical Trial Update: Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease [Phase 3]
A Phase 3 clinical trial evaluating two doses of EVP-6124 in Alzheimer's disease was terminated.
-
CLINICAL_TRIALS withdrawal · 2016-05-03Clinical Trial Update: Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease [Phase 3]
A Phase 3 study evaluating two doses of EVP-6124 in Alzheimer's disease was terminated.
-
CLINICAL_TRIALS trial_result · 2016-04-22Clinical Trial Update: Study in Elderly Alzheimer's Patients to Assess Skin Tolerability, Irritation With 3, 7-Day Applications of DTP-System [Phase 2]
Phase 2 trial assessing skin tolerability and irritation with 3- and 7-day applications of the DTP-System in elderly Alzheimer's patients ha…
-
CLINICAL_TRIALS trial_result · 2016-04-21Clinical Trial Update: Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease [Phase 1, Phase 2]
A Phase 1/2 trial evaluating Bryostatin 1 in Alzheimer's disease was terminated, with results posted in 2016 assessing safety, efficacy, pha…
-
FDA approval · 2016-04-19FDA Approved: GALANTAMINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for galantamine from Aurobindo Pharma Limited, enabling continued market approval as a generic optio…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-04-19FDA Approved: GALANTAMINE HYDROBROMIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for galantamine hydrobromide from Sun Pharmaceutical Industries, Inc. under an ANDA, granting author…
-
CLINICAL_TRIALS trial_result · 2016-04-19Clinical Trial Update: Effect of AQW051 in Patients With Memory Impairment [Phase 2]
Phase 2 trial of AQW051 in memory impairment (Mild Alzheimer's disease and amnestic mild cognitive impairment) has been terminated.
-
CLINICAL_TRIALS trial_result · 2016-04-18Clinical Trial Update: Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease [Phase 2]
A Phase 2 clinical trial by VTBIO Co. LTD investigated optimal dosage and administration for Alzheimer's disease; the study has completed.
-
CLINICAL_TRIALS trial_result · 2016-04-18Clinical Trial Update: Retrospective Cohort Study Of The Efficacy Of Axona® (Medium Chain Triglycerides) In Patients With Alzheimer's Disease
This report outlines the results of a retrospective cohort study evaluating the efficacy of Axona, a medium-chain triglyceride product, in p…
-
FDA approval · 2016-04-11FDA Approved: FLUDEOXYGLUCOSE F18 — Original Application (Kreitchman PET Center)
The FDA approved Fludeoxyglucose F18 through an Original Application filed by Kreitchman PET Center for use as a radiopharmaceutical in PET …
-
FDA approval · 2016-04-07FDA Approved: VIZAMYL — Supplemental Application (GE Healthcare Inc. (Medi-Physics, Inc. dba GE Healthcare))
FDA approves a supplemental application for Vizamyl (flutemetamol F-18) from GE Healthcare. The approval updates the product labeling to ref…
-
CLINICAL_TRIALS trial_result · 2016-04-01Clinical Trial Update: A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease [Phase 2]
A long-term extension Phase 2 study of the Alzheimer's vaccine ACC-001 with QS-21 in mild to moderate Alzheimer's disease was terminated, an…
-
CLINICAL_TRIALS trial_result · 2016-03-31Clinical Trial Update: Effect of NeuroAD on the Cognitive Function of Alzheimer Patients [NA]
Clinical trial update indicating the completion of a study evaluating NeuroAD for cognitive function in Alzheimer's disease patients.
-
CLINICAL_TRIALS trial_result · 2016-03-30Clinical Trial Update: Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease [Phase 2]
A Phase 2 clinical trial is evaluating the efficacy and safety of the PET imaging agent [18F]NAV4694 in subjects with probable Alzheimer's d…
-
CLINICAL_TRIALS trial_result · 2016-03-28Clinical Trial Update: Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions [Phase 2]
Phase 2 trial assessing the effect of EGb761 (Ginkgo biloba extract) on brain glucose metabolism in elderly participants categorized by cogn…
-
CLINICAL_TRIALS research · 2016-03-25Clinical Trial Update: Is There a Relationship Between Previous Exposure to General Anesthesia and the Development of Alzheimer´s Disease?
This clinical trial update investigates whether prior exposure to general anesthesia is related to the development of Alzheimer's disease, w…
-
FDA approval · 2016-03-25FDA Approved: RIVASTIGMINE TARTRATE — Original Application (Aurobindo Pharma Limited)
FDA approved an original generic application for rivastigmine tartrate from Aurobindo Pharma Limited, enabling a generic version of rivastig…
-
CLINICAL_TRIALS trial_result · 2016-03-24Clinical Trial Update: Semantic Memory, Financial Capacity, and Brain Perfusion in Mild Cognitive Impairment (MCI) (CASL)
The update summarizes results from a completed clinical trial evaluating semantic memory, financial capacity, and brain perfusion in individ…
-
CLINICAL_TRIALS research · 2016-03-22Clinical Trial Update: Omental Transposition Surgery for Mild Alzheimer's Disease [NA]
This clinical trial update concerns omental transposition surgery as a potential treatment for mild Alzheimer's disease. It is sponsored by …
-
CLINICAL_TRIALS trial_result · 2016-03-17Clinical Trial Update: Effects of Light-therapy in Alzheimer's Disease [NA]
Clinical trial updating the effects of light-therapy for Alzheimer's disease has completed, indicating the study has reached its completed s…
-
CLINICAL_TRIALS trial_result · 2016-03-14Clinical Trial Update: Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil [Phase 2]
A Phase 2 trial evaluated different doses of SAR110894 on cognition in patients with mild to moderate Alzheimer's disease who are on donepez…
-
FDA approval · 2016-03-09FDA Approved: AMYVID — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for AMYVID (Florbetapir F-18) submitted by Eli Lilly. This action confirms continued regulatory …
-
FDA approval · 2016-03-08FDA Approved: NEURACEQ — Supplemental Application (Lantheus Biosciences Ltd.)
The FDA approved a supplemental application for NEURACEQ (FLORBETABEN F 18) from Lantheus Biosciences Ltd.
-
CLINICAL_TRIALS research · 2016-03-08Clinical Trial Update: Memory Problems Perceptions Among Patients and Accompaniers During Diagnosis Process : [NA]
A clinical trial update describing perceptions of memory problems among patients and their accompaniers during the diagnostic process, spons…
-
CLINICAL_TRIALS trial_result · 2016-03-08Clinical Trial Update: Alzheimer's Disease Multiple Intervention Trial [NA]
This update indicates that the Alzheimer's disease multiple intervention trial at Indiana University has completed.